Direct-to-consumer (DTC) marketing of pharmaceuticals is controversial, yet effective. Little is known relating patterns of medication use to patient responsiveness to DTC.
Methods
We conducted a secondary analysis of data collected in national telephone survey on knowledge of and attitudes toward DTC advertisements. The survey of 1081 U.S. adults (response rate = 65%) was conducted by the Food and Drug Administration (FDA). Responsiveness to DTC was defined as an affirmative response to the item: "Has an advertisement for a prescription drug ever caused you to ask a doctor about a medical condition or illness of your own that you had not talked to a doctor about before?" Patients reported number of prescription and over-the-counter (OTC) medicines taken as well as demographic and personal health information.
Results
Of 771 respondents who met study criteria, 195 (25%) were responsive to DTC. Only 7% respondents taking no prescription were responsive, whereas 45% of respondents taking 5 or more prescription medications were responsive. This trend remained significant (p trend .0009) even when controlling for age, gender, race, educational attainment, income, self-reported health status, and whether respondents "liked" DTC advertising. There was no relationship between the number of OTC medications taken and the propensity to discuss health-related problems in response to DTC advertisements (p = .4).
Conclusion
There is a strong cross-sectional relationship between the number of prescription, but not OTC, drugs used and responsiveness to DTC advertising. Although this relationship could be explained by physician compliance with patient requests for medications, it is also plausible that DTC advertisements have a particular appeal to patients prone to taking multiple medications. Outpatients motivated to discuss medical conditions based on their exposure to DTC advertising may require a careful medication history to evaluate for therapeutic duplication or overmedication.
Considerable controversy surrounds the practice of direct-to-consumer (DTC) marketing of pharmaceuticals. While some argue that DTC advertising serves as an educational resource for patients,[1] others say that DTC advertising contributes to the medicalization of trivial ailments, and leads to overuse and misuse of pharmaceuticals[2]. Since initially allowed by the Food and Drug Administration in 1985,[3] spending on DTC advertising grew steadily over the following decade. DTC advertising spending accelerated rapidly after 1997, when the Food and Drug Administration provided draft guidance which described how sponsors could disseminate information on drugs and biological products using radio and television [4, 5]. Pharmaceutical industry expenditures for DTC advertising increased 330% between 1996 and 2005. In 2005, $4.2 billion was spent on DTC advertising, which accounted for 14% of all promotional spending for prescription drugs[6]. Expenditures have decreased (in absolute terms) since 2007 following a peak of $5.4 billion in 2006 [7].
Although it is difficult to find data on the effectiveness of DTC advertising for individual drugs, 10-35% of survey respondents say they have discussed medical conditions or medications with their physicians as a result of DTC advertising[8–10]. Furthermore, patients who specifically request medications during an office visit are much more likely to receive them than those who do not[9, 11–13].
While much has been written regarding consumer and physician attitudes toward DTC advertising, less is known relating patient characteristics, notably medication use, and responsiveness to DTC advertising. One survey found that responders to DTC advertising were more likely to be nonwhite, have lower educational attainment and lower income,[10] whereas Bell found that women, as well as persons with a positive attitude towards DTC advertising, in poorer self-reported health, and with better self-reported insurance coverage of medications were more likely to respond to DTC advertising[9]. This survey also found that persons using prescription drugs at the time of the interview were more likely to be influenced by DTC advertising. To further investigate the relationship between self-reported medication use and responsiveness to DTC advertising, we conducted a secondary analysis of data obtained in an FDA survey of exposure to, perceptions of, and attitudes toward DTC advertising.
Methods
Data Source
The data come from a national telephone survey of adults in the U.S., investigating the demographic characteristics and attitudinal effects of DTC prescription drug advertising of survey respondents[5]. The survey was conducted by a professional research firm for the Food and Drug Administration between April and July 1999 to examine attitudes and influence of DTC advertising of prescription drugs upon the healthcare experience. The target population for the survey was English speaking consumers aged 18 or older.
Respondents were contacted using random digit dialing methodology and several steps were taken to optimize the response rate. Interviews were scheduled for varying times of the day in an effort to locate potential respondents at a convenient time. Respondents were allowed to schedule "call back" appointments to complete the survey at a more convenient time. Unlimited call backs (more than 40) were utilized for phone numbers that did not initially yield a respondent contact. Respondents who initially refused to participate, or terminated the interview before completion were contacted by a mailed follow-up letter as well as two follow-up telephone solicitations.
Study Population
1081 persons responded to the survey representing a response rate of 65% (eligible respondents who completed survey plus ineligible respondents divided by the total contacted minus bad telephone numbers). From these, 310 persons who had not been exposed to DTC prescription drug marketing in the three months prior to the survey, and therefore did not answer the question of interest, were excluded. Table 1 describes those persons excluded from the analysis. Thus our study population included 771 persons.
Table 1
Characteristics of Respondents Not Exposed to DTCA, Excluded From Study
Characteristic
Prevalence
Age
Less than 65 years
72.0
65 years or older
28.0
Gender
Male
35.2
Female
64.8
Race
White
66.5
Non-white
33.5
Marital Status
Married
49.7
Single, widowed, divorced, other
50.3
Educational Attainment
College graduate or higher
23.2
Some college or less
76.8
Annual Income
Less than $35,000
57.9
$35,000 or more
42.1
Time since last visit to physician
Within one month
40.7
More than one month
59.3
Self-reported health
Excellent
17.8
Very Good
29.1
Good
27.2
Fair
18.1
Poor
7.8
Mean # of Rx drugs in past 6 months
2 (S.D. 1.6)
Mean # of OTC drugs in past 6 months
1.2 (S.D. 1.2)
n = 310
Main Measures
"Responsiveness to DTC drug marketing" was defined as an affirmative response to the survey item: "Has an advertisement for a prescription drug ever caused you to ask your doctor about a medical condition or illness of your own that you had not talked to a doctor about before?" Prescription and OTC drug use was determined using the self-reported number of prescription drugs, and OTC drugs used within the six month period prior to the survey.
Covariates
Covariates were also determined from the survey. These included gender, race, income, marital status, date of last physician visit, self-reported health, self-reported knowledge about health and medications, and attitude toward DTC drug advertisements. Self-reported health was assessed with a single item using a five point scale ranging from 1 ("excellent" health) to 5 ("poor" health). Self-reported knowledge about health and medications was assessed with a single item using a four point scale ranging from 1 ("extremely" knowledgeable) to 5 ("not at all" knowledgeable). Attitude toward DTC drug advertisements was assessed with a single item asking how much the respondent "liked" DTC advertising with responses on a five point scale ranging from 1 ("strongly agree") to 5 ("strongly disagree").
Statistical Analysis
We used T-test and chi-square tests for univariate analyses. For multivariate analysis, we used logistic regression controlling for covariates. These covariates included age, gender, race, educational attainment, marital status, income, self-reported health status, self-reported knowledge of medicines and health, and attitude toward DTC advertising. We performed all analyses using SAS version 9.1 (SAS Institute Inc, Cary, NC). All p-values were 2-sided and α was set at .05.
Results
Characteristics of the Study Sample
The average respondent's age was (mean ± s.d.) 46.1 ± 15.7 years, 64% were female, and 81% were white. Forty-two percent had completed at least a college degree and 57% were married at time of interview. On average, respondents had encountered 2.4 ± 1.3 modes of delivery of DTC prescription drug advertising (e.g. magazines, television, newspaper, etc.) in the three months prior to the interview. Respondents' mean score for how much they "liked seeing" these advertisements was 2.7 ± 1.4. The mean response for respondents' self-reported knowledge of medications and health matters in general was 2.6 ± 0.7. Similarly, mean response for respondents' self-reported health status was 2.4 ± 1.1 see Table 2.
Table 2
Sample Characteristics by Responsiveness to DTC Advertising
Covariate
Prevalence
Proportion responsive to DTC advertising
Multivariate association with responsiveness to DTC advertising (OR, 95% CI)
Age
Less than 65 years
85.9
23.2
2.5 (1.5-4.1)
65 years or older
14.1
37.6
Gender
Male
36.1
22.2
1.0 (.7-1.5)
Female
63.8
27.3
Race
White
82.6
24.5
.7 (.4-1.0)
Non-white
17.4
31.1
Marital Status
Married
57.5
25.5
1.1 (.7-1.6)
Single, widowed, divorced, other
42.1
25.0
Educational Attainment
College graduate or higher
57.8
28.9
.7 (.4-1.0)
Some college or less
42.1
20.3
Annual Income
Less than $35,000
48.6
25.8
1.2 (.8-1.9)
$35,000 or more
51.3
24.8
Self-reported health
Excellent
23.2
13.4
1.1 (1.0-1.4)
Very Good
41.4
25.1
Good
22.1
32.9
Fair
11.9
28.5
Poor
4.4
44.1
Time since last visit to physician
Within one month
59.6
27.4
.9 (.6-1.4)
More than one month
40.4
22.2
Self-reported knowledge about health and medications
Extremely knowledgeable
8.8
22.1
1.0 (.8-1.3)
Very knowledgeable
30.0
25.5
Somewhat knowledgeable
58.2
25.4
Not at all
3.0
26.1
Like seeing advertisements for prescription drugs
Strongly agree
20.4
41.6
1.4 (1.2-1.6)
Agree somewhat
31.0
24.4
Neither agree or disagree
20.8
20.7
Disagree
10.9
18.1
Strongly disagree
16.9
15.5
n = 771
Relationship between Respondent Characteristics and Responsiveness to DTC Marketing
Overall, 195 (25.3%) respondents answered affirmatively to our variable of interest, indicating that they had initiated discussion of a medical problem with their physician based on DTC advertising. Compared to respondents who denied discussing medical problems with their physicians based on DTC advertising, respondents who used DTC advertising as a foundation for discussing a new health problem with their physician were older, possessed less educational attainment, and "liked" seeing DTC prescription drug advertisements. Gender, race, marital status, self-reported health status, self-reported knowledge about health and medications, and income were not significantly associated with the primary endpoint (see Table 2).
Relationship between Self-Reported Prescription Medication Use and Responsiveness to DTC Marketing
The mean number of prescription drugs used in the six months prior to the survey was 2.4 ± 1.6. Of 108 persons using no prescription medications, 9 (8.3%) were responsive to DTC advertisements. Of 131 persons using five or more prescription medicines, 50 (38.1%) were responsive to DTC advertisements. There was a strong trend (p < .0001) in the relationship between number of prescription medications used and responsiveness to DTC advertisements. This association remained highly significant (p = .0009) even when controlling for demographics, self-reported health status, educational attainment, race, marital status, self-reported knowledge of medications and health, number of OTC medications used, income, and attitude toward DTC advertisements see Figure 1.
Figure 1
Proportion of respondents who were responsive to direct-to-consumer (DTC) advertising, by number of self-reported prescription medications used in six months prior to study. The number of respondents in each category is embedded in the bars.
Relationship between Self-Reported OTC Medication Use and Responsiveness to DTC Marketing
The average number OTC drugs used in the six months prior to the survey was 1.8 ± 1.4. Of 136 persons using no OTC medications, 44 (32.3%) were responsive to DTC. Of 61 persons using five or more OTC medicines, 20 (32.7%) were responsive to DTC. There was no linear trend in either univariate (p = .54.) or multivariate (p = .76) relationship between number of OTC medications used and responsiveness to DTC see Figure 2.
Figure 2
Proportion of respondents who were responsive to direct-to-consumer (DTC) advertising, by number of self-reported non-prescription medications used in six months prior to study. The number of respondents in each category is embedded in the bars.
Discussion
Our data indicate that a cross-sectional relationship exists between number of prescription drugs used and "responsiveness" to DTC advertising. This strong linear relationship remains even when controlling for demographic and socioeconomic variables and self-reported health. Overall, 25.3% of respondents were motivated by DTC advertising to initiate discussion regarding new health problems. Among respondents taking no prescription medications, fewer than 10% were motivated by DTC advertising. Conversely, among respondents taking five or more prescription medicines, nearly 40% were motivated.
In 2002, the Government Accountability Office has identified 13 surveys, primarily for lay publications, which attempted to assess consumer behavior related DTC advertising[8]. Since that time several additional surveys have been published in the medical and scientific literature[10, 14–16]. In these studies, the proportion of respondents who reported being influenced by DTC advertising to seek medical care ranged from 10.5 to 35%. Although there is some variation in how each survey defines responsiveness to DTC advertising, our finding that 25% of respondents had discussed a new medical condition with a physician based on DTC advertising is generally consistent with others.
Our results confirm those of previous studies, [10, 17] which identify older age, lower educational attainment and a positive attitude towards DTC advertising as factors associated with responsiveness to DTC advertising[9, 10]. In contrast to other studies, [14, 18] we did not find an association between ethnicity, income or self-reported health status and DTCA.
We found that a cross-sectional relationship exists between responsiveness to DTC and self-reported use of prescription, but not OTC, drugs. Because there was a trend towards poorer self-reported health and responsiveness to DTC, is plausible that users of prescription medications represent a sicker population, and one that may be more attuned to the messages conveyed in DTC advertising. Alternatively, because DTC advertising largely focuses on prescription medications, persons who are responsive to DTC may have approached their prescribers based on information in DTC, resulting in more prescription, rather than OTC, use. Bell and colleagues found that current users of prescription drugs were more likely to be influenced by DTC advertising,[9] but did not quantify the number of prescriptions, and limited their sample to one county in California.
Our investigation confirms results of a smaller study of Minnesotans by Schommer et al. [15] that found prescription medication use to be statistically greater in respondents who were responsive to DTC advertising than those who were not. Similar to our results, no significant difference was found in the number of OTC medications used by responsive versus unresponsive patients.
The main strength of our study is that the source of data comes from a large nationally representative sample with a high response rate. Furthermore, unlike some other studies, OTC as well as prescription drug use was ascertained. Our study has several limitations. First, these data were collected in 1999. Penetration and awareness of DTC advertising, as well as types of media outlets (e.g. internet), have increased considerably in subsequent years. Despite this, however, we are encouraged by similarities in regard to attitudinal, socioeconomic and demographic predictors of susceptibility to DTC advertising demonstrated in more recent surveys, [14, 15] and likewise feel that the relationship between number of prescription drugs used and susceptibility to DTC advertising should be no less true today. Second, this is a secondary analysis of FDA data originally collected to investigate attitudinal and demographic effects toward DTC advertising; thus, rigorous ascertainment of medication use was not included. Although the self-reported medication use measure is a limitation, it has been used in a previous survey of DTC advertising,[15] and has been found to be congruent with pharmacy prescription data[19, 20].
The cross-sectional nature of this study does not allow for unequivocal statements regarding the direction of causality. Although this relationship could be explained by physician compliance with patient requests for medications, it is also plausible that DTC advertisements have a particular appeal to patients prone to taking multiple medications. Finally, the main measure in this study specifically asks about initiating discussion with a physician about a new medical problem and thus may not have captured those patients who use DTC advertisements to prompt discussion of previously discussed problems, or those patients who may have discontinued a medication due to information contained in DTC advertisements.
Conclusion
There is a strong cross-sectional relationship between the number of prescription, but not OTC, drugs used and responsiveness to DTC advertising. Although this relationship could be explained by physician compliance with patient requests for medications, it is also plausible that DTC advertisements have a particular appeal to patients prone to taking multiple medications. Outpatients motivated to discuss medical conditions based on their exposure to DTC advertising may require a careful medication history to evaluate for therapeutic duplication or overmedication.
Further research needs to be performed to understand this population's eagerness to utilize prescription drugs and to determine if this eagerness transcends to utilization of other health care resources. Clearly, these DTC advertisements are powerful motivators. Perhaps they could be used to enhance evidence-based prescribing and advance public health.
Declarations
Acknowledgements
This research was supported in part by the 21st Century Scholars Program, The Urban Child Institute, Memphis, TN. The authors would like to thank Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and Communications, Center for Drug Evaluation and Research, Food and Drug Administration for her helpful comments; and Kathryn M. Jemmott, M.A., MSW for her editorial assistance. Material in this paper presented as: Dieringer NJ, Shorr RI. Effectiveness of direct to consumer advertising among the already medicated. (Poster Presentation at the 27th Annual Meeting of the Society for General Internal Medicine, Chicago, IL 5/04)
Authors’ Affiliations
(1)
Department of Medical Education, Methodist Healthcare
(2)
GRECC (182) NF/SG Veterans Health System
(3)
Department of Preventive Medicine, University of Tennessee Health Science Center
(4)
Department of Aging and Geriatric Research, University of Florida
References
Holmer AF: Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999, 281: 380-382. 10.1001/jama.281.4.380.View ArticlePubMedGoogle Scholar
Rados C: Truth in Advertising: Rx Drug Ads Come of Age. FDA Consum. 2004, 38 (4): 20-27.Google Scholar
Wilkes MS, Bell RA, Kravitz RL: Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood). 2000, 19: 110-128. 10.1377/hlthaff.19.2.110.View ArticleGoogle Scholar
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM: Promotion of prescription drugs to consumers. N Engl J Med. 2002, 346: 498-505. 10.1056/NEJMsa012075.View ArticlePubMedGoogle Scholar
Donohue JM, Cevasco M, Rosenthal MB: A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007, 357: 673-681. 10.1056/NEJMsa070502.View ArticlePubMedGoogle Scholar
Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. (GAO-03-177). 2002, Washington, D.C.: United States General Accounting OfficeGoogle Scholar
Bell RA, Kravitz RL, Wilkes MS: Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med. 1999, 14: 651-657. 10.1046/j.1525-1497.1999.01049.x.View ArticlePubMedPubMed CentralGoogle Scholar
Robinson AR, Hohmann KB, Rifkin JI, Topp D, Gilroy CM, Pickard JA, Anderson RJ: Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med. 2004, 164: 427-432. 10.1001/archinte.164.4.427.View ArticlePubMedGoogle Scholar
Understanding the Effects of Direct-to-Consumer Prescription Drug Advertising. Henry J Kaiser Family Foundation. Published November 29, 2001. Accessed August 7, 2011, [http://www.kff.org/rxdrugs/3197-index.cfm]
Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P: Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005, 293: 1995-2002. 10.1001/jama.293.16.1995.View ArticlePubMedPubMed CentralGoogle Scholar
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA: Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002, 324: 278-279. 10.1136/bmj.324.7332.278.View ArticlePubMedPubMed CentralGoogle Scholar
Murray E, Lo B, Pollack L, Donelan K, Lee K: Direct-to-consumer advertising: public perceptions of its effects on health behaviors, health care, and the doctor-patient relationship. J Am Board Fam Pract. 2004, 17: 6-18. 10.3122/jabfm.17.1.6.View ArticlePubMedGoogle Scholar
Schommer JC, Singh RL, Hansen RA: Distinguishing characteristics of patients who seek more information or request a prescription in response to direct-to-consumer advertisements. Res Social Adm Pharm. 2005, 1: 231-250. 10.1016/j.sapharm.2005.03.009.View ArticlePubMedGoogle Scholar
Khanfar N, Loudon D, Sircar-Ramsewak F: FDA direct-to-consumer advertising for prescription drugs: what are consumer preferences and response tendencies?. Health Mark Q. 2007, 24: 77-91. 10.1080/07359680802125899.View ArticlePubMedGoogle Scholar
Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, Feibelmann S: Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff (Millwood). 2004, W4-33. Suppl Web ExclusivesGoogle Scholar
Lee D, Begley CE: Racial and ethnic disparities in response to direct-to-consumer advertising. Am J Health Syst Pharm. 2010, 67: 1185-1190. 10.2146/ajhp090600.View ArticlePubMedGoogle Scholar
Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG: Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006, 15: 710-718. 10.1002/pds.1226.View ArticlePubMedGoogle Scholar
Caskie GI, Willis SL: Congruence of self-reported medications with pharmacy prescription records in low-income older adults. Gerontologist. 2004, 44: 176-185. 10.1093/geront/44.2.176.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
